January 27, 2019 — Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute…Original Article
FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine
